The Learning Portal will be under maintenance Friday, 28 January from 10PM to 12AM. Portal functionality may be unavailable intermittently during this window.
We apologize for any inconvenience caused during this time.

  • Regulatory NewsRegulatory News

    India Looks to Cap Prices of 12 Cancer Drugs as Nation Looks to Expand Price Controls

    The cost of 12 cancer drugs could soon be capped in India if a recommendation from the country's National Pharmaceutical Pricing Authority (NPPA) is approved, The Indian Express reports. At the same time, the government is actively looking into revising its National List of Essential Medicines (NLEM) following a proposal from a parliamentary committee for price caps to be extended to all drugs two weeks ago. Background In India, the prices of drugs listed under t...
  • Regulatory NewsRegulatory News

    Indian Parliament Proposes Extending Price Caps to all Drugs

    Just weeks after India's drug pricing chief was ousted, a parliamentary committee has proposed expanding price caps to all drugs. Background In India, the price of drugs listed as essential medicines is capped by the National Pharmaceutical Pricing Authority (NPPA) under the country's Drug Price Control Order (DPCO) . The amount these drugs can be sold for is indexed to average wholesale prices of similar products, and can only be increased once per year, as was th...
  • India's Drug Pricing Authority Announces Stiff Fines for Violators of Price Limits

    India's National Pharmaceutical Pricing Authority (NPPA) has released a new guideline indicating that companies that overcharge Indian consumers may be liable for recovery damages as high as the entirety of the product's sales in the country. The guideline, dated 12 October 2012, explains that it believes, "It is absolutely essential that manufacturers and marketing companies should not sell their scheduled formulations at unauthorized and illegitimate prices to earn u...
  • India Poised to Restrict Price Hikes, Cut Margins

    The Indian National Pharmaceutical Pricing Authority (NPPA) will limit price hikes by foreign drug companies by more closely scrutinizing the profit margins of companies that declare higher production costs, according to a reporter for the Economic Times of India . Imported brands are currently restricted to selling drugs above their production costs by anywhere between 35-50%, depending on the presence of generic market competition.  This price ceiling is known ...